The cure rates in the clinically evaluable population were similar in the telavancin ( @ % , @/@ ) and vancomycin ( @ % , @/@ ) groups -LSB- treatment difference ( @ % CI ) : @ % ( -@ % to @ % ) -RSB- , and were consistent with the overall ATTAIN study results .